Abstract: An apparatus for mixing a liquid in a container in order to provide a homogeneous solution or suspension of the liquid in the container. In particular, the apparatus of this invention can be used to provide a homogenous dispersion of particulate material in a liquid medium.

Abstract: A crystalline N-(4-(4-aminothieno[2,3 -d]pyrimidin-5-yl)phenyl)-N?-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate characterized in the monoclinic crystal system and P21/n space group, when measured with radiation at 0.7107 ?, by lattice parameters a, b and c of 5.0318 ?±0.006 ?, 23.684 ?±0.002 ? and 18.877 ?±0.002 ?, respectively, and ? of 90.703±0.003, ways to make it, compositions comprising it, and methods of treatment using it are disclosed.

Abstract: A crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N?-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate characterized in the triclinic crystal system and P-1 space group, when measured with radiation at 0.7107 ?, by lattice parameters a, b and c of 7.800 ?±0.001 ?, 13.406 ?±0.002 ? and 13.554 ?±0.002 ?, respectively and ?, ? and ? of 67.155±0.002, 79.724°±0.002° and 84.067±0.002, respectively, ways to make it, compositions comprising it, and methods of treatment using it are disclosed.

Abstract: Anti-IL-18 antibodies are disclosed herein, including antigen-binding portions thereof. One or more methods for isolating and purifying anti-IL-18 antibodies from a sample matrix is presented. These isolated anti-IL-18 antibodies can be used in a clinical setting as well as in research and development. Pharmaceutical compositions comprising isolated anti-IL-18 antibodies are also described.

Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Abstract: Compounds of Formula (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), method of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising compound of Formula (I).

Abstract: Ac-Sar-Gly-Val-D-allo-Ile-Thr-Nva-Ile-Arg-ProNHCH2CH3 Crystalline Form 1, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.

Abstract: Anti-IL-12 antibodies are disclosed herein, including antigen-binding portions thereof. One or more methods for isolating and purifying anti-IL-12 antibodies from a sample matrix is presented. These isolated anti-IL-12 antibodies can be used in a clinical setting as well as in research and development. Pharmaceutical compositions comprising isolated anti-IL-12 antibodies are also described.

Abstract: A system for automation of laboratory analyzers that utilizes radio frequency identification (RFID) tags and radio frequency identification (RFID) readers to identify containers and vessels, and the contents thereof, that are employed in the system. Radio frequency identification tags, conforming to the guidelines of ISO 14443 or ISO 15693 or ISO 18000, are positioned on the items of interest, such as, for example, reagent containers, sample containers, and microplates. These tags can be read by and written to by either a moving antenna of a RFID reader or a stationary antenna of a RFID reader. Reading of RFID tags and writing to RFID tags are controlled by software.

Abstract: A slide holder comprising a rectangular frame having two side walls facing each other, a first end wall facing a second end wall, the second end wall having a latch pivotally attached thereto, the latch capable of being pivoted in such a manner as to enable locking and unlocking of the slide holder in a slide holder carrier. The slide holder carrier has a first end wall, a first side wall, a second end wall, a second side wall, and a shaft running from the first end wall of the slide holder carrier to the second end wall of the slide holder carrier. At least one slide holder is rotatably mounted on the shaft.

Abstract: A module for staging sample tubes and mixing the samples contained in the sample tubes for an automated clinical analyzer. In one embodiment, this module comprises a mixing drum, which is capable of mixing the contents of a sample tube in an end-over-end manner. The mixing drum is capable of mixing samples in the sample tubes without separating the solid components of the sample, e.g., red blood cells from the liquid components of the sample, e.g., plasma. A device for elevating the sample tube in the sample tube carrier can be used to enable the cap of the sample tube to be punctured by a piercing element in a piercing assembly. After the cap of the sample tube is punctured, a probe for aspirating the sample from said sample tube can obtain the sample in the receptacle of the sample tube through a bore in the piercing element. The piercing assembly can include a resiliently biased element for ejecting the sample tube from the piercing assembly.

Abstract: A method for enumerating white blood cells and nucleated red blood cells. The steps of the method are as follows: (a) providing a lysed sample of whole blood; (b) introducing the lysed sample to a light-scattering multi-angle depolarizing flow cytometer; (c) removing depolarizing interference, e.g., lipid droplets and other measured particles; (d) differentiating nucleated red blood cells and noise from white blood cells in the absence of depolarizing interference; (e) differentiating nucleated red blood cells from noise in the absence of depolarizing interference and white blood cells; and (f) differentiating possible platelet clumps.

Abstract: The present invention relates to methods for making stable test samples that can be used in ligand-binding assays for measuring natriuretic peptides.

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.

Abstract: A handling device for samples and reagents to be used in testing in a system. Carriers of samples and reagents are loaded on a platform which detects the presence of, and proper loading of, such carriers. The carriers are moved from the platform by a transporter to a bar code reader for identification. A reagent container is rotated during reading to facilitate identification. The transporter further moves identified reagent carriers to a carousel on which the carriers automatically secured for storage awaiting use in testing. The carousel rotates, and selected reagent containers rotate on the rotating carousel, during storage.

Abstract: The invention provides probe washing cups and methods. A probe washing cup has a washing well and a waste cup. A drying section is disposed between an open end of the probe washing cup and an inlet plane of the washing well. The drying section has a channel that is aligned with the washing well. The channel has an opening for receiving the probe therethrough.

Abstract: Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences and especially the gp41 IDR of isolate HAM112. Also claimed are polynucleotide sequences encoding the above, expression vectors comprising the same, host cells transformed thereby, and immunoassay methods and kits utilizing the antigen constructs of the invention.

Abstract: Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences and especially the gp41 IDR of isolate HAM112. Also claimed are polynucleotide sequences encoding the above, expression vectors comprising the same, host cells transformed thereby, and immunoassay methods and kits utilizing the antigen constructs of the invention.

Abstract: Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences and especially the gp41 IDR of isolate HAM112. Also claimed are polynucleotide sequences encoding the above, expression vectors comprising the same, host cells transformed thereby, and immunoassay methods and kits utilizing the antigen constructs of the invention.